Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Kerrigan

Showing results (41-50 of 90) with videos related to

Pageof 9
Sort By:
Cancer Research|December 1, 1984
Enhancement of the DNA breakage and cytotoxic effects of intercalating agents by treatment with sublethal doses of 1-beta-D-arabinofuranosylcytosine or hydroxyurea in L1210 cellsJ Minford, D Kerrigan, M Nichols, et al.
Cancer Research|June 1, 1986
Altered DNA topoisomerase II activity in Chinese hamster cells resistant to topoisomerase II inhibitorsY Pommier, D Kerrigan, R E Schwartz, et al.
Biochemical Pharmacology|September 1, 1992
Overexpression of P-glycoprotein and alterations in topoisomerase II in P388 mouse leukemia cells selected in vivo for resistance to mitoxantroneN Kamath, D Grabowski, J Ford, et al.
Gut|November 1, 1991
Influence of acid-pepsin secretion on gastric emptying of solids in humans: studies with cimetidineD D Kerrigan, Y F Mangnall, N W Read, et al.
Journal of Reproduction and Fertility|July 1, 1987
Long-term study of the immuno-pathological consequences of sympathetic orchiopathia in the ratD I Lewis-Jones, R V Lynch, D D Kerrigan, et al.
NCI Monographs : a Publication of the National Cancer Institute|January 1, 1987
Topoisomerase II as a target of anticancer drug action in mammalian cellsK W Kohn, Y Pommier, D Kerrigan, et al.
Cancer Communications|January 1, 1990
10,11-Methylenedioxycamptothecin, a topoisomerase I inhibitor of increased potency: DNA damage and correlation to cytotoxicity in human colon carcinoma (HT-29) cellsP M O'Connor, D Kerrigan, R Bertrand, et al.
Gut|August 1, 1993
Acid, motility, and ulcers: a comparison of cisapride with placebo in the prevention of duodenal ulcer relapseD D Kerrigan, M E Taylor, N W Read, et al.
Cancer Communications|January 1, 1989
Progressive resistance to doxorubicin in mouse leukemia L1210 cells with multidrug resistance phenotype: reductions in drug-induced topoisomerase II-mediated DNA cleavageR Ganapathi, D Grabowski, J Ford, et al.
Biochemical Pharmacology|October 15, 1982
Protein-associated deoxyribonucleic acid strand breaks produced in mouse leukemia L1210 cells by ellipticine and 2-methyl-9-hydroxyellipticiniumL A Zwelling, S Michaels, D Kerrigan, et al.
Pageof 9

Showing results (41-50 of 90) with videos related to

Sort By:
Pageof 9
Cancer Research|December 1, 1984
Enhancement of the DNA breakage and cytotoxic effects of intercalating agents by treatment with sublethal doses of 1-beta-D-arabinofuranosylcytosine or hydroxyurea in L1210 cellsJ Minford, D Kerrigan, M Nichols, et al.
Cancer Research|June 1, 1986
Altered DNA topoisomerase II activity in Chinese hamster cells resistant to topoisomerase II inhibitorsY Pommier, D Kerrigan, R E Schwartz, et al.
Biochemical Pharmacology|September 1, 1992
Overexpression of P-glycoprotein and alterations in topoisomerase II in P388 mouse leukemia cells selected in vivo for resistance to mitoxantroneN Kamath, D Grabowski, J Ford, et al.
Gut|November 1, 1991
Influence of acid-pepsin secretion on gastric emptying of solids in humans: studies with cimetidineD D Kerrigan, Y F Mangnall, N W Read, et al.
Journal of Reproduction and Fertility|July 1, 1987
Long-term study of the immuno-pathological consequences of sympathetic orchiopathia in the ratD I Lewis-Jones, R V Lynch, D D Kerrigan, et al.
NCI Monographs : a Publication of the National Cancer Institute|January 1, 1987
Topoisomerase II as a target of anticancer drug action in mammalian cellsK W Kohn, Y Pommier, D Kerrigan, et al.
Cancer Communications|January 1, 1990
10,11-Methylenedioxycamptothecin, a topoisomerase I inhibitor of increased potency: DNA damage and correlation to cytotoxicity in human colon carcinoma (HT-29) cellsP M O'Connor, D Kerrigan, R Bertrand, et al.
Gut|August 1, 1993
Acid, motility, and ulcers: a comparison of cisapride with placebo in the prevention of duodenal ulcer relapseD D Kerrigan, M E Taylor, N W Read, et al.
Cancer Communications|January 1, 1989
Progressive resistance to doxorubicin in mouse leukemia L1210 cells with multidrug resistance phenotype: reductions in drug-induced topoisomerase II-mediated DNA cleavageR Ganapathi, D Grabowski, J Ford, et al.
Biochemical Pharmacology|October 15, 1982
Protein-associated deoxyribonucleic acid strand breaks produced in mouse leukemia L1210 cells by ellipticine and 2-methyl-9-hydroxyellipticiniumL A Zwelling, S Michaels, D Kerrigan, et al.
Pageof 9